M. Wernerwasik et al., PROGNOSTIC FACTORS FOR LOCAL AND DISTANT RECURRENCE IN STAGE-I AND STAGE-II CERVICAL-CARCINOMA, International journal of radiation oncology, biology, physics, 32(5), 1995, pp. 1309-1317
Citations number
19
Categorie Soggetti
Oncology,"Radiology,Nuclear Medicine & Medical Imaging
Purpose: The effects of tumor size, parametrial involvement, and other
variables on treatment outcome for patients with Federation Internati
onale de Gynecologic et d'Obstetrique (PICO) Stage I or II cervical ca
rcinoma, as well as treatment complications, were analyzed retrospecti
vely. Methods and Materials: Records of 125 patients with FIGO Stage I
or II carcinoma of the uterine cervix selected for curative radiother
apy between January 1980 and December 1990 were reviewed. Twelve patie
nts (9.9%) underwent adjuvant extrafascial hysterectomy and 8 patients
(6.4%) received chemotherapy. Median age was 55 years. Median follow-
up time was 40 months, and minimum follow-up time was 24 months. The d
ata were analyzed for site of first relapse, survival, overall inciden
ce of complications, and incidence of grade 4 complications. Results:
The overall 5-year survival was: Stage IA: 100%, Stage IB: 72%, Stage
IIA: 90%, and Stage IIB: 72%. The 5-year survival with no evidence of
disease (NED) was: Stage IA: 100%, Stage IB: 67%, Stage IIA: 90%, and
Stage IIB: 50%. Patients with bulky (> 5 cm) tumors had a shorter over
all and NED survival than patients with nonbulky tumors (53% vs. 83%;
p = 0.0008 and 44% vs. 78%; p = 0.0001, respectively). Thirty-nine tum
or recurrences (39 out of 125 = 31%) occurred and were scored as local
(23 out of 125 = 18.3%), if initial failure had a local component, or
distant (16 out of 125 = 12.7%), if initial failure was distant only,
Patients with bulky (more than 5 cm) tumors (32 out of 125) were more
likely to experience a recurrence (18 out of 32 = 56%) than patients
with nonbulky tumors (21 out of 93 = 22%; p = 0.0004). The initial sit
e of recurrence was more likely to be local for bulky tumors (14 out o
f 18 = 78%) than for nonbulky tumors (9 out of 21 = 43%;p = 0.03). The
probability of a recurrence increased with the number of involved par
ametria (none: 20 out of 78 = 25%; one: 12 out of 34 = 35%; two: 7 out
of 13 = 54%;p = 0.04 for linear trend), as did the probability that t
he initial failure was distant rather than local (none: 4 out of 20 =
20%; one: 7 out of 12 = 58%; two: 5 out of 7 = 71%; p = 0.01 for linea
r trend). Positive lymph nodes, vessel invasion, and low :hemoglobin l
evel all correlated with an increased risk of a recurrence (RR 2.41, p
= 0.004; RR 2.20, p = 0.01; OR 2.02, p = 0.01, respectively). There w
ere 46 complications among 37 (29%) patients. The incidence of grade 4
complications was 8.8% (11 out of 125). History of pelvic surgery and
bulky tumor were significant predictors of a grade 4 complication (p
< 0.0001 and 0.021, respectively). Also, a dose rate to point A of > 0
.6 Gy/h increased the chance of a grade 4 complication (p = 0.007). Co
nclusion: For patients with PICO Stage I or II cervical carcinoma, tum
or size was more predictive of local recurrence than was overall stage
, and the extent of parametrial involvement was strongly predictive of
distant recurrence, as was the stage. These findings suggest that tum
or size and extent of parametrial involvement should be incorporated i
nto the staging system. Patients with bulky tumors had a shorter survi
val and were more likely to experience a grade 4 toxicity of therapy.
Dose rate to point A of > 0.6Gy/h was associated with the increased ri
sk of grade 4 complications.